Pharma Matthew Herper STAT Plus: After its drug was shown to prevent heart attacks, what’s next for Esperion?
Health Damian Garde and Matthew Herper STAT Plus: Heart repair, risky genes, and AI: the buzz from a giant cardiovascular conference
Pharma Matthew Herper STAT Plus: Esperion Therapeutics’ statin alternative reduces heart attack risk. Is that enough to save the company?
Health Matthew Herper One type of artificial sweetener may increase heart attack risk, preliminary study says
Health Tech Ambar Castillo STAT Plus: Tools to predict stroke risk work less well for Black patients, study finds
Health Tech Lizzy Lawrence STAT Plus: A device restored hand movement for two stroke survivors. Researchers want to take it mainstream
First Opinion Nisha Parikh and Alison Cowan Pregnancy complications heighten heart risks in later life. It’s time to pay attention
Health Katherine Harmon Courage Racism leads to troubled sleep — and it’s putting Black Americans’ heart health at risk
Health Tech Mario Aguilar STAT Plus: Apple scores victory in dispute over heart monitoring technologies in Apple Watch
Health Tech Mario Aguilar STAT Plus: ‘Who is the real pioneer?’: Apple and AliveCor go head-to-head over crucial heart monitoring tech for smartwatches
Health Katherine Harmon Courage A simple screening question could help millions of women prevent cardiovascular disease. Why aren’t we using it?
Health Usha Lee McFarling Brains of Black Americans age faster, study finds, with racial stressors a likely factor
Biotech Damian Garde STAT Plus: Data show strong results for Alnylam therapy for heart disease, but magnitude of benefit will stir debate
Health Tech Mario Aguilar STAT Plus: An ambitious stroke prevention study tests the Apple Watch’s promise in health
Health Katherine Gilyard Study: religious practice, spirituality can improve Black Americans’ cardiovascular health
In the Lab Elizabeth Cooney New research digs into the genetic drivers of heart failure, with an eye to precision treatments
Biotech Damian Garde STAT Plus: Alnylam therapy for increasingly common heart disease succeeds in closely watched trial
The Readout LOUD Damian Garde and Adam Feuerstein Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’
Biotech Matthew Herper and Megan Molteni STAT Plus: Verve Therapeutics begins human tests of first ‘base editor,’ aiming at heart disease
Biotech Matthew Herper STAT Plus: New analysis of Amarin’s Vascepa resurrects big questions about effectiveness
Health Akila Muthukumar Valliammai STAT Plus: Popular drug may have new benefit in men with diabetes, but not women, study shows
Pharmalot Ed Silverman STAT Plus: High blood pressure pills are costly — but also hard to find — in some lower-income countries
Matt's Take Matthew Herper STAT Plus: Robert Califf is a fervent believer in data. At the FDA, will that be enough?
Special Report Damian Garde STAT Plus: It’s the cardiovascular version of Alzheimer’s — and, for a biotech with a promising drug, it could be a windfall
Health Elizabeth Cooney ‘Information alone is not enough’: New Jackson Heart Study leader commits to putting research into action